RAPID Coverage Pathway: What It Means for Device Makers

The coverage gap between FDA clearance and Medicare reimbursement has been one of the most persistent frustrations in the medical device industry — and for good reason. A device can clear FDA review and still wait years before Medicare beneficiaries can actually access it. CMS and FDA are now taking a direct run at that problem.

On May 5, 2025, CMS and FDA jointly announced the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway. The announcement, published at FDA.gov, represents the most significant structural change to the FDA-CMS alignment conversation in years. For device manufacturers, particularly those pursuing Breakthrough Device Designation, this changes the strategic calculus in meaningful ways.

What the RAPID Pathway Actually Does

Under the RAPID pathway, certain FDA-designated Class II and Class III Breakthrough Devices will be eligible for immediate Medicare coverage upon FDA market authorization — bypassing the traditional, drawn-out National Coverage Determination (NCD) process that has historically added anywhere from 1 to 3 years of delay after clearance or approval.

The traditional pathway works something like this: a manufacturer obtains FDA clearance, then CMS conducts its own independent evidence review, often issuing a Coverage with Evidence Development (CED) requirement that demands additional post-market data before full coverage is granted. Devices can sit in that limbo for years while the Medicare population — often the exact patients who need these technologies most — goes without access.

RAPID changes that default by creating a coordinated review mechanism where FDA's Breakthrough Device evidence standards and CMS's coverage criteria are aligned from an earlier stage of development. The result, in theory, is that market authorization and coverage eligibility arrive together rather than sequentially.

To be eligible, a device must hold FDA's Breakthrough Device Designation and receive market authorization (either 510(k) clearance, De Novo, or PMA approval) under that designation. Not every Breakthrough Device will automatically qualify — there are criteria around clinical evidence sufficiency that manufacturers will need to meet — but the pathway creates a structured route to simultaneous authorization and coverage that simply didn't exist before.

Why This Gap Existed in the First Place

It's worth understanding why the FDA-CMS coverage gap became such a stubborn problem before we get too optimistic about the fix.

FDA and CMS operate under entirely different statutory frameworks with different evidentiary standards. FDA asks whether a device is safe and effective for its intended use. CMS asks whether it is "reasonable and necessary" for Medicare beneficiaries — a standard that incorporates cost-effectiveness considerations, comparative effectiveness against existing covered alternatives, and sometimes evidence specific to the Medicare population (which is often older and has more comorbidities than the populations studied in pivotal trials).

Those are genuinely different questions, and that gap has produced real harm. According to a 2022 analysis published in the Journal of the American College of Cardiology, FDA-authorized cardiovascular devices faced an average CMS coverage delay of 26 months after market authorization. In that same period, the patients who arguably needed those devices most — elderly Medicare beneficiaries — had no covered access to them.

The FDA's Breakthrough Device program, established under the 21st Century Cures Act and later formalized, has also grown substantially. As of early 2025, FDA had granted more than 1,000 Breakthrough Device Designations since the program launched, with approximately 50–60 new designations granted per quarter. The volume alone signals why a coordinated coverage solution became urgent.

The Strategic Implications for Device Manufacturers

If you're a manufacturer with an active Breakthrough Device Designation — or if you're considering pursuing one — RAPID changes your planning assumptions in at least three concrete ways.

Coverage strategy now begins at the trial design stage. One of the key implications of RAPID is that manufacturers who want to use this pathway will need to engage CMS earlier, not just FDA. If the pathway requires coordinated evidence review, the clinical trial protocols that generate your FDA authorization evidence will also need to address CMS's coverage criteria. That means thinking about the Medicare population's representation in your pivotal study, designing endpoints that speak to "reasonable and necessary" questions, and potentially having parallel conversations with both agencies during the pre-submission process.

In my experience working with device companies on regulatory strategy, the biggest mistake manufacturers make is treating FDA clearance as the finish line. RAPID doesn't let you make that mistake as easily — because the pathway essentially forces the CMS conversation into the development timeline, not after it.

Breakthrough Device Designation just got more valuable. The designation already conferred real benefits — interactive review, prioritized FDA attention, and the ability to discuss coverage with CMS through the Breakthrough Device Coverage Pilot (the predecessor framework to RAPID). Now it potentially unlocks simultaneous market authorization and Medicare coverage. For investors and acquirers evaluating a device company, a Breakthrough designation combined with RAPID eligibility should carry meaningfully more weight in valuation discussions than it did twelve months ago.

Pricing and market access strategy will compress. When coverage follows authorization immediately, the commercial launch timeline changes. Historically, device companies built 18–24 months of post-authorization runway into their commercial planning to account for coverage uncertainty. With RAPID, that runway may compress to 6 months or less. That sounds like good news — and it mostly is — but it also means manufacturing scale-up, contracting with health systems, and commercial team deployment all need to be ready at authorization, not 18 months after it.

What the Data Tells Us About the Coverage Gap Problem

A few numbers worth having in hand when you're explaining the significance of this to your board or your investors:

According to a 2021 study in Health Affairs, only 12% of novel FDA-authorized medical devices received Medicare coverage within the first year of market authorization. The median time from FDA authorization to Medicare coverage for high-risk devices in that study was approximately 3 years. Studies examining the Medicare Coverage of Innovative Technology (MCIT) rule — which CMS proposed in 2021 but later rescinded — found that Breakthrough Devices addressed conditions affecting approximately 3.7 million Medicare beneficiaries annually. That's the scale of the access problem RAPID is designed to address.

Comparing RAPID to Previous Coverage Alignment Efforts

This isn't CMS and FDA's first attempt to solve the coverage gap problem. It's helpful to understand what came before — and why those efforts fell short.

The MCIT rule is instructive here. CMS finalized it in January 2021, then rescinded it in September 2021 after concerns that blanket 4-year coverage regardless of evidence quality was too blunt an instrument. The criticism was that it would encourage coverage of devices that hadn't generated sufficient evidence of benefit for Medicare beneficiaries specifically.

RAPID appears designed to thread that needle — providing faster coverage, but only when the evidence meets a coordinated threshold that both agencies have agreed to in advance. That's a meaningfully different architecture than MCIT, and in my view it's more likely to survive both political and legal scrutiny as a result.

The Compliance Angle: What Manufacturers Need to Do Now

If you have a Breakthrough Device in development or in late-stage clinical trials, there are practical steps worth taking now rather than waiting for full program guidance.

Request a Q-Sub (Pre-Submission) with FDA that specifically addresses RAPID eligibility. FDA's Pre-Submission program allows manufacturers to ask questions about trial design, regulatory pathway, and now, presumably, RAPID eligibility criteria. Getting clarity early on whether your device and evidence package will meet the RAPID threshold is worth doing before you lock your pivotal trial protocol.

Initiate a CMS coverage analysis in parallel. CMS offers a formal Coverage Analysis process, and some manufacturers engage CMS through their Medicare Administrative Contractors (MACs) for informal guidance as well. Either route gives you early signal on whether your evidence strategy addresses the "reasonable and necessary" standard.

Audit your clinical data for Medicare population representativeness. One of the most common gaps I see in device submissions is that the pivotal trial enrolled a younger, healthier population than the Medicare beneficiaries who will actually use the device. If your trial data skews toward patients under 65 with fewer comorbidities, that's a problem for CMS even if it satisfies FDA.

Build your commercial infrastructure earlier. If RAPID delivers on its promise, you need to be operationally ready at authorization day, not after it. That includes contracting strategy, coding and billing infrastructure, and health economics data that supports your list price and any value-based arrangement you're pursuing with payers.

For manufacturers who want help thinking through how RAPID intersects with their specific regulatory and commercial strategy, reach out to Certify Consulting for a strategy session. With over 200 clients served and a 100% first-time audit pass rate, we've helped device companies navigate every major regulatory shift of the last decade — this one included.

Honest Uncertainty: What RAPID Doesn't Yet Resolve

I want to be direct about what we don't know, because I think the coverage of this announcement has been a bit rosier than the practical reality warrants.

First, the specific eligibility criteria for RAPID have not yet been fully published in the form of binding guidance. What CMS and FDA have announced is the pathway's existence and general framework. The actual evidentiary thresholds — what "sufficient evidence" means in the context of coordinated review — will be defined in subsequent guidance, and that guidance will matter enormously to manufacturers trying to determine whether their device qualifies.

Second, RAPID is currently scoped to Medicare. Commercial payers, Medicaid, and CHIP are not part of this framework. For many device companies, Medicare is the dominant payer in their target population, so this is still hugely significant — but it's not a complete market access solution on its own.

Third, the pathway's effectiveness will depend heavily on execution. The FDA-CMS coordination this requires is genuinely novel from an operational standpoint. Both agencies will need dedicated resources, clear communication protocols, and management commitment to make parallel review work in practice. The Parallel Review Program that's been available since 2016 has seen relatively limited uptake in part because the coordination burden was real, even when the pathway was theoretically available.

RAPID is a meaningful step forward. In my view, it's the most promising structural change to the coverage gap problem we've seen. But manufacturers should plan for a ramp-up period where the process is being worked out in practice, not just in policy documents.

What This Means for Patients

There's a temptation in regulatory strategy discussions to stay entirely in the business and compliance frame. But the patient access dimension of RAPID is worth naming directly.

The devices that carry Breakthrough Designation typically address serious or life-threatening conditions where no adequate alternatives exist. When those devices clear FDA and then spend years in CMS coverage limbo, Medicare beneficiaries — who are disproportionately older and more likely to have the conditions these devices address — are the ones who go without. That's not an abstract policy problem; it's a real harm.

A 2023 JAMA Network Open study found that Medicare beneficiaries were 40% less likely than commercially insured patients to have access to newly authorized high-risk medical devices within the first two years of market authorization. RAPID, if it works as intended, directly addresses that disparity.

The Bottom Line

RAPID is real, it matters, and it changes the strategic picture for Breakthrough Device manufacturers in ways that will require updated planning assumptions now — not after the full guidance is finalized.

The core insight is this: if you're pursuing Breakthrough Designation and you're not already thinking about CMS alongside FDA in your development strategy, you're behind. RAPID makes the two-agency parallel strategy the expected approach, not the exceptional one. The manufacturers who adapt their clinical, regulatory, and commercial planning accordingly will have a meaningful structural advantage over those who treat this as a future consideration.

The coverage gap has cost patients and manufacturers alike for too long. In my view, this is a genuine attempt to fix it — and for once, it's worth some cautious optimism.

Related reading: Understanding FDA Breakthrough Device Designation: A Strategic Guide | Medical Device Regulatory Strategy Services at Certify Consulting

Last updated: 2026-05-05

Jared Clark, JD, MBA, PMP, CMQ-OE, CQA, CPGP, RAC is the Principal Consultant at Certify Consulting. He has served 200+ medical device and life sciences clients across 8+ years of FDA regulatory consulting.